Received 21 February 1990/Accepted 26 June 1990
To perform a human immunodeficiency virus (HIV) plaque assay in nonadherent host cells, we developed a novel technique in which HIV-infected MT-2 cells were formed into monolayers by centrifugation through molten agarose. Infection, formation of cell monolayers, and enumeration of plaques all took place in 96-well microtiter plates. When this process was preceded by 18 h of incubation of HIV with patient serum samples, neutralizing antibody titers between 1:10 and 1:5,000 could be accurately determined in patient serum samples. In addition to the determination of neutralizing antibody titers (with the use of various serum dilutions and a constant virus concentration), neutralization indices could also be determined with different virus dilutions and a single dilution of patient serum.
Titration of infectious human immunodeficiency virus (HIV) and determination of HIV neutralizing antibody titers have been impeded by the lack of an adherent host cell line in which stained viral plaques may be enumerated by traditional techniques. It has been possible, however, to quantify HIV neutralization in vitro by measuring a reduction in HIV reverse transcriptase (RT) activity (11) , HIV-induced syncytia (10), HIV-induced host cell death (12, 14) , HIV-induced immunofluorescence (3) , and HIV-induced cytopathic effects (1) . A plaque assay with HIV-vesicular stomatitis virus pseudotype viruses has also been used to measure HIV neutralization on vesicular stomatitis virus-sensitive cells (18) . More recently, HIV-sensitive MT-2 and MT-4 cells have been formed into monolayers on poly-L-lysine-coated plates to permit the use of traditional neutral red staining techniques (9, 19) .
Useful information has been obtained by these methods, although the amount of data has sometimes been limited by the laborious techniques involved. In comparison to those for other viral diseases, most HIV neutralizing antibody titers observed to date have been relatively low (2, 5, 13, 18) . It is unclear whether this is an intrinsic feature of HIV infection or is the result of limitations of the assays used.
We report here a novel method for titration of HIV which is capable of revealing a wide range of HIV neutralizing antibody titers in human sera and which has the following features. (i) HIV-sensitive MT-2 cells are formed into monolayers by centrifugal force under molten agarose. (ii) The HIV-induced microplaques (0.1 to 1.0 mm in diameter) which are formed are sufficiently small to allow statistically significant numbers of plaques to be enumerated under low-power magnification in individual wells of a 96-well microtiter plate. The efficiency of microtiter plates permits the use of replicate wells to determine data scatter and calculate standard deviations. (iii) Visualization and rapid counting of the unusually small plaques is made possible by use of a bright fluorescent stain which is taken up by the HIV-induced syncytia which compose the microplaques. Fibrin was removed by adding 1 ml of sterile 1 M CaCl2 per 100 ml of plasma and allowing a clot to form for several hours at room temperature. During subsequent overnight incubation at 4°C, the clot retracted and was spun off at 2,000
x g for 15 min. The plasma was filtered through a 0.45-pmpore cellulose acetate filter.
Each unit was tested in the MT-2 microplaque assay for its ability to potentiate the growth of HIV type 1. Those units with strong potentiating activity (greater than or equal to that of previously used normal human plasma pools [NHPP]) were pooled, divided into aliquots, and frozen at -20°C until used.
HIV microplaque assay. The assay medium was 85%
Dulbecco modified Eagle medium (with a high glucose concentration) containing 100 pug of streptomycin, 100 U of penicillin, 50 ,ug of gentamicin, and 1 ,ug of amphotericin B per ml, 15% fetal bovine serum, and 2 ,ug of Polybrene (Sigma Chemical Co., St. Louis, Mo.) per ml. Virus and sera to be tested were diluted in 50% assay medium and 50% NHPP. Test sera were first inactivated at 56°C for 30 min and then serially diluted directly in 96-well plates (Corning Glass Works, Corning, N.Y.). Virus (0.025 ml) diluted to contain approximately 20 PFU was added to each well containing 0.025 ml of diluted serum and to each control well containing 0.025 ml of diluent only. The plates were mixed on an oscillatory shaker for 30 s and incubated at 37°C in a 5% C02 atmosphere for 1 to 18 h. MT-2 cells (0.025 ml) were added to each well to give a concentration of 90,000 cells per well.
After an additional 1 h of incubation at 37°C in 5% C02, 0.075 ml of assay medium containing 1.6% SeaPlaque agarose (FMC Bioproducts, Rockland, Maine) and prewarmed to 38.5°C was added to each well. The plates were kept at 370C
for a few minutes until several plates had accumulated and then centrifuged in plate carriers at 600 x g for 20 min in a centrifuge precooled to 10°C. In the centrifuge, cell monolayers formed prior to gelling of the agarose layer. counts as a function of serum dilution. Using a curve fit to the data points by nonlinear least-squares regression analysis, the Lotus worksheet interpolated the serum dilution, if any, at which there was a 50% reduction in the average plaque count relative to the average plaque count in the control wells.
On the basis of the standard error of the mean (SEM) of the 12 control well values and the SEM of each point on the neutralization curve, it was possible to compute a probable error of the interpolated 50% neutralizing serum dilution (T. Speed, personal communication). Briefly, by use of an iteratively reweighted least-squares method, the data were fit to a logistic function: F (x) = exI(l + ex). In this process, the data points with greatest variance were given the least weight. The quasi-Newton minimization method used in the least-squares procedure yielded the standard error of each parameter, including that of the serum dilution at which 50% neutralization occurred. By this approach, the data scatter among the replicate wells was taken into account in deriving a measure of the precision (standard error) of the interpolated 50% neutralizing antibody titer.
Neutralization index assay. All media for the neutralization index assay were the same as those used for the microplaque assay. Test sera and negative control serum were inactivated, diluted 1:10 or 1:15 in assay diluent with 50% NHPP, and delivered to a microtiter plate at 0.025 ml per well. Logarithmic dilutions of the test virus were made in assay diluent and added to the microtiter plate at 0.025 ml per well, with four to eight replicates per dilution. Serum and virus were mixed and incubated for 18 h at 37°C in a moist 5% C02 atmosphere. The addition of cells and agarose, incubation, and staining were the same as those for the microplaque assay.
Plaques were counted at those dilutions in which 5 to 20 plaques per well were present, and the logarithmic titer for each test serum was subtracted from that of the negative control serum to give the neutralization index.
RESULTS
MT-2 and MT-4 cells demonstrate a characteristic cytopathic response to HIV infection which facilitates the observation of microplaques. Within 3 to 5 days after infection, syncytia are formed and cell membranes become permeable to propidium iodide. Upon excitation with mid-range UV light, propidium iodide emits red fluorescence after intercalating with cellular nucleic acids. An example of microplaques is shown in Fig. 1 .
The planting density of the cells affects the growth rate and viral plaque size. The cells are most sensitive to viral infection in the logarithmic growth phase, but very rapid cell growth results in large, spreading plaques which are difficult to distinguish and count. Cell densities of 30,000 to 120,000 per well (32.1 mm2) were investigated. The optimum cell density was determined to be 60,000 to 90,000 cells per well.
Cell densities within this range did not significantly affect total plaque counts, neutralization kinetics, or standard errors.
We have found that to maintain uniform properties, the MT-2 clone alpha-4 cells must periodically be replaced with cells at a lower passage number. A decline in growth rate to less than two doublings in 96 h precedes a loss of up to 50% of viral sensitivity and an unacceptable increase in the time required for plaques to form. We have also evaluated other T-lymphocyte cell lines: CEM-SS (10) (provided by Peter Nara), SKT-1B (6) (provided by Atsushi Koito), and CEM x-174 (16) and Sup-T-1 (17) (provided by James Hoxie). All failed to produce sufficiently rapid, lytic, cytopathic effects that would react with the fluorescent stain.
Ethidium bromide, widely used in nucleic acid studies, is Typical results of applying the microplaque assay to the measurement of neutralizing antibody titers are shown in Fig. 2 .
To improve upon low neutralizing antibody titers previously reported, we deemed it desirable to minimize noninfectious viral antigen which might compete with detectable infectious virions for binding to the neutralizing antibodies. This was achieved by preferential recovery of the virus associated with the host cell from which it buds in mature, infectious form. Reproducible virus stocks were easily made by mechanically shearing or hypotonically shocking infected cells (without releasing the intracellular contents). The stocks were examined by electron microscopy (L. Oshiro, this laboratory) to determine the amount of cellular debris and incomplete virus present. These preparations were compared with a crude virus preparation used in our earlier studies and made in parallel from the same infected cells by disruption with three cycles of freeze-thaw followed by clarification at 2,000 x g for 15 min. The latter preparation was observed to contain a significantly greater amount of cellular debris, which was presumed to be accompanied by a greater amount of extraneous viral antigen.
Titration of human and animal sera for neutralizing activity in the absence of NHPP showed that sera without detectable antibody to HIV could potentiate the expression of HIV by producing larger, more numerous plaques. In an effort to control these variable serum effects, we incorporated 50% normal human serum into the diluent used for both the sera and virus. After the addition of all the components, the final concentration of NHPP during culturing was 16%, a concentration which gave maximum plaque titers without being toxic for the cells. Nearly all of the normal human plasmas tested to date have increased the 50% tissue culture infective doses of HIV by at least 100-fold in this system. Some cytotoxic plasmas and the least efficient plasmas were excluded from the pools. Increasing the con- centration of fetal bovine serum in the diluent can also raise HIV titers, but not as efficiently as human plasma. Heating of NHPP or fetal bovine serum was avoided, since heat inactivation of NHPP at 56°C for 30 min reduced this potentiating activity by 30 to 40%. The heat-labile serum component involved may be complement, consistent with the finding of complement receptors on MT-2 cells (15).
The MT-2 cell line is an HTLV type I-transformed human T-cell line that resulted from the cocultivation of cord blood lymphocytes and leukemic cells from a patient with adult T-cell leukemia and produces virus particles as well as viral antigens at the cell surface (8) . To determine whether the presence of anti-HTLV type I antibody would affect the assay, we determined the titers of HIV-positive and -negative antisera in the presence of HTLV type I-positive and -negative antisera. No differences were observed in neutralizing antibody titer or in virus control plaque counts (data not shown).
The effects of virus-serum incubation time and temperature on neutralizing antibody titer, control plaque number, and data scatter (standard error) were studied with an HIV-positive human serum pool ( Table 1 ). The combination of physiologic temperature (37°C) and, most importantly, prolonged incubation greatly increased the resulting neutralizing antibody titers. Compared with a traditional 1-h incu- b With a standardized pool of sera from HIV-seropositive human subjects.
bation, however, incubation (in 50% NHPP) for 18 h or more at 37°C resulted in thermal inactivation of half the viral inoculum and an ensuing increase in statistical error. Thus, optimum assay conditions were obtained at this incubation time and temperature by doubling the viral inoculum. AIthough neutralizing antibody titers were still 40-fold higher than with a 1-h incubation, nonimmune sera showed no neutralization at the lowest dilution tested (1:5); thus, the dynamic range of the assay was dramatically increased. The effects of four pHs, within the range of 6.6 to 7.4, on neutralization were determined by controlling the pH with N-2-hydoxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) and morpholineethanesulfonic acid (MES) buffers (Sigma). At a given temperature and incubation time, neutralization curves were identical at the various pHs, but plaque counts were slightly reduced and their standard errors were slightly increased at pH 6.6 (data not shown).
We have also applied the microplaque technique to a determination of neutralization indices, an alternative method for determining the neutralizing capacity of a serum sample. A constant concentration of serum was reacted with logarithmically diluted virus, and the neutralization index was expressed as the logarithmic dose of virus neutralized. Table 2 shows a comparison of neutralizing antibody titers and neutralization indices for the same human patient sera, both as determined by the microplaque method.
The micro-plaque method reported here is also applicable 
DISCUSSION
While it is possible to quantify HIV indirectly by measuring the expression of viral antigen or RT activity, there are important advantages to plaque assays, in which infectious foci are enumerated. Different strains of HIV differ in the expression of RT on a per-virion basis, for example (7) . While partial neutralization may be accurately determined by plaque reduction, the reduction of viral RT or antigen expression is transient and, in contrast to plaque reduction titers, neutralization titers in the latter assays can change with time of incubation as "breakthrough" occurs. The detection of infectious virus in plaques also avoids problems involved in the subtraction of "background" due to noninfectious viral antigen or RT activity.
The within-run accuracy of the microplaque assay is excellent, as may be seen from the standard error values for plaque counts in replicate wells (Table 1 and Fig. 2A) . Thus, subtle changes in plaque count may be discerned, and the use of 50% reduction as an endpoint (as opposed to the often-used 80% reduction) appears to be justified and helps to extend the dynamic range of the assay. The HIV antibody-positive pool included as a positive standard in every run also permits a measure of day-to-day reproducibility. On the basis of these data, we prefer to interpret conservatively only twofold or greater differences in neutralizing antibody titer as significant.
The neutralization index is less commonly determined than is the neutralizing antibody titer-partly because of the need for greater volumes of test sera. It could be argued, however, that the neutralization index may more accurately reflect humoral immunity as it occurs in the undilute blood in vivo. It was therefore of interest to establish whether the microplaque method could be used to determine neutralization indices for eventual comparison with the clinical status of patients. Regression analysis of the data in Table 2 , however, showed that the neutralization index is highly correlated (r = 0.85) with (the logarithm of) the neutralizing antibody titer. Thus, while the utility of neutralization index measurements for HIV antibody remains to be determined, it is unlikely that the correlation, if any, with clinical status will differ from that obtained with neutralizing antibody titer measurements.
In summary, the advantages of the microplaque assay include accurate endpoints, a large dynamic range, and rapidity. The assay is potentially useful for titration of infectious HIV, quantitative HIV inactivation studies, tests of the efficacy of anti-HIV agents, and measurements of the neutralization titer and neutralization index of HIV antibodies. The novel technique of plaque formation in nonadherent cell fines immobilized after centrifugation in agarose may also be applicable to other virus-host cell systems.
